{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:11:57Z","timestamp":1791090717233,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ctrv.2012.12.005","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T23:06:59Z","timestamp":1356736019000},"page":"584-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Malignant mesothelioma: New insights into a rare disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Lianes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Zanui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2012.12.005_b0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/oem.2007.034769","article-title":"Mesothelioma mortality in men: trends during 1977\u20132001 and projections for 2002\u20132016 in Spain","volume":"65","author":"Pitarque","year":"2008","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.ctrv.2012.12.005_b0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","article-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience","volume":"16","author":"Curran","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.ctrv.2012.12.005_b0020","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Hollevoet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5858\/arpa.2010-0604-RA","article-title":"Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma","volume":"136","author":"Betta","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2012.12.005_b0030","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/RLI.0b013e3181817b3d","article-title":"Computed tomography, positron emission tomography, positron emission tomography\/computed tomography, and magnetic resonance imaging for staging of limited pleural mesothelioma: initial results","volume":"43","author":"Plathow","year":"2008","journal-title":"Invest Radiol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2012.12.005_b0050","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma","volume":"7","author":"Lang-Lazdunski","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0055","unstructured":"Rusch V, Giroux D, Kennedy C, et al. Initial analysis of IASLC mesothelioma database, In: 14th World conference on lung cancer; 2011, p. O30.01."},{"key":"10.1016\/j.ctrv.2012.12.005_b0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0169-5002(02)00180-0","article-title":"Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis","volume":"38","author":"Berghmans","year":"2002","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0070","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/bjc.1992.200","article-title":"High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study","volume":"65","author":"Solheim","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0075","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0080","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0085","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2005.03.3027","volume":"24","author":"Bottomley","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2011.07.011","article-title":"Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma","volume":"75","author":"Woods","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0095","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1586\/era.11.136","article-title":"Raltitrexed in mesothelioma","volume":"11","author":"Surmont","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2012.12.005_b0100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","article-title":"The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline","volume":"1","author":"Ellis","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0105","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","article-title":"Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial","volume":"371","author":"Muers","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.12.005_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study","volume":"17","author":"Byrne","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","article-title":"A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma","volume":"87","author":"Nowak","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","article-title":"Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia","volume":"64","author":"Lee","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0125","first-page":"7082","article-title":"Malignant pleural mesothelioma (MPM) in elderly patients: a multicenter survey","volume":"30","author":"Grosso","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0140","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0145","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2007.14.7611","article-title":"Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma","volume":"26","author":"Janne","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0150","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdj073","article-title":"A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial","volume":"17","author":"O\u2019Brien","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00520-005-0837-0","article-title":"Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso","volume":"14","author":"Hollen","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0160","first-page":"7084","article-title":"Outcomes of sarcomatoid malignant pleural mesothelioma, a distinct clinical entity","volume":"30","author":"Gattoni","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0165","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0175","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2012.12.005_b0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01243894-200601000-00007","article-title":"Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma","volume":"1","author":"van den Bogaert","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0006-2952(03)00287-9","article-title":"Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression","volume":"66","author":"Sigmond","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0200","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.hoc.2005.09.008","article-title":"Antiangiogenic therapies for mesothelioma","volume":"19","author":"Dowell","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ctrv.2012.12.005_b0205","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","volume":"75","author":"Kao","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0210","first-page":"7006","article-title":"A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy","volume":"29","author":"Baas","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0215","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/bjc.2011.129","article-title":"Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer","volume":"104","author":"Takezawa","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0220","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.005_b0225","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0230","first-page":"7024","article-title":"Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma","volume":"29","author":"Christoph","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0235","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6605501","article-title":"The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy","volume":"102","author":"Nutt","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0240","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1158\/1078-0432.CCR-03-0156","article-title":"Ribonucleotide reductase messenger RNA expression and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"10","author":"Rosell","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.005_b0245","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2012.12.005_b0250","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/cncr.26522","article-title":"Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis","volume":"118","author":"Simon","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0255","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/FPC.0b013e32834e3572","article-title":"The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma","volume":"22","author":"Erculj","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ctrv.2012.12.005_b0260","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2012.12.005_b0265","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.semtcvs.2009.07.003","article-title":"Making the case for molecular staging of malignant pleural mesothelioma","volume":"21","author":"Bueno","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ctrv.2012.12.005_b0270","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.005_b0275","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2009.09.003","article-title":"Second-line treatment for malignant pleural mesothelioma","volume":"36","author":"Ceresoli","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2012.12.005_b0285","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"Janne","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0290","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6673-3-34","article-title":"Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study","volume":"3","author":"Xanthopoulos","year":"2008","journal-title":"J Occup Med Toxicol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0300","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0305","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0310","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0315","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/JTO.0b013e3181c5e366","article-title":"Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials","volume":"5","author":"Paik","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0320","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLC.2006.n.003","article-title":"Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid","volume":"7","author":"Krug","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0325","unstructured":"Krug L. Suberoylanilide hydroxamatic acid (vorinostat) versus placebo in advanced malignant pleural mesothelioma, In: VANTAGE 014 trial, European multidisciplinary cancer congress; 2011."},{"key":"10.1016\/j.ctrv.2012.12.005_b0330","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase ii trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0340","first-page":"7020","article-title":"IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II\/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma","volume":"28","author":"Zalcman","year":"2010","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0345","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0350","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0355","first-page":"7027","article-title":"Cediranib (C) in patients (pts) with malignant mesothelioma (MM): a phase II trial of The University of Chicago Phase II Consortium","volume":"29","author":"Campbell","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0360","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.005_b0365","first-page":"7076","article-title":"NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)","volume":"30","author":"Rossoni","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0370","first-page":"7026","article-title":"Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response","volume":"29","author":"Hassan","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0375","first-page":"7030","article-title":"Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: results of a multicenter phase II clinical trial","volume":"30","author":"Hassan","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0380","first-page":"7077","article-title":"Phase II trial of anti-transforming growth factor-beta (TGFss) monoclonal antibody GC1008 in relapsed malignant pleural mesothelioma (MPM)","volume":"30","author":"Stevenson","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0385","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000087376","article-title":"Serum PDGF-AB in pleural mesothelioma","volume":"26","author":"Filiberti","year":"2005","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0390","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0395","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2012.12.005_b0400","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2012.12.005_b0405","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0410","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-011-1655-3","article-title":"Review on clinical trials of targeted treatments in malignant mesothelioma","volume":"68","author":"Jakobsen","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0420","first-page":"7029","article-title":"Randomized phase II trial of pemetrexed\/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM)","volume":"30","author":"Krug","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0425","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (Cancer and Leukemia Group B 30601): a brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2012.12.005_b0430","first-page":"7507","article-title":"Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)","volume":"27","author":"Reck","year":"2009","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0435","first-page":"7083","article-title":"SWOG 0722: a phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM)","volume":"30","author":"Garland","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2012.12.005_b0440","first-page":"7081","article-title":"Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052","volume":"30","author":"O\u2019Brien","year":"2012","journal-title":"ASCO Meeting Abstracts"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737212002447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T20:37:47Z","timestamp":1539981467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737212002447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":88,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0305737212002447"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant mesothelioma: New insights into a rare disease","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}